Entity Details

Primary name CHRND
Entity type gene
Source Source Link

Details

PrimaryID1144
RefseqGeneNG_008028
SymbolCHRND
Namecholinergic receptor nicotinic delta subunit
Chromosome2
Location2q37.1
TaxID9606
Statuslive
SourceGenomegenomic
SourceOriginnatural
CreationDate1989-05-01
ModificationDate2021-06-11

Ontological Relatives

UniProt IDsACHD_HUMAN

GO terms

Show/Hide Table
GOName
GO:0003009 skeletal muscle contraction
GO:0004888 transmembrane signaling receptor activity
GO:0005654 nucleoplasm
GO:0005829 cytosol
GO:0005886 plasma membrane
GO:0005887 integral component of plasma membrane
GO:0005892 acetylcholine-gated channel complex
GO:0006936 muscle contraction
GO:0007165 signal transduction
GO:0007268 chemical synaptic transmission
GO:0022848 acetylcholine-gated cation-selective channel activity
GO:0030594 neurotransmitter receptor activity
GO:0031594 neuromuscular junction
GO:0034220 ion transmembrane transport
GO:0042166 acetylcholine binding
GO:0042391 regulation of membrane potential
GO:0043005 neuron projection
GO:0045202 synapse
GO:0045211 postsynaptic membrane
GO:0048630 skeletal muscle tissue growth
GO:0050877 nervous system process
GO:0050881 musculoskeletal movement
GO:0050905 neuromuscular process
GO:0099060 integral component of postsynaptic specialization membrane
GO:1904315 transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential

Diseases

Show/Hide Table
Disease IDSourceNameDescription
616323 OMIMMyasthenic syndrome, congenital, 3C, associated with acetylcholine receptor deficiency (CMS3C)A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS3C is an autosomal recessive disorder of postsynaptic neuromuscular transmission, due to deficiency of AChR at the endplate that results in low amplitude of the miniature endplate potential and current. The disease is caused by variants affecting the gene represented in this entry.
253290 OMIMMultiple pterygium syndrome, lethal type (LMPS)Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent. The disease is caused by variants affecting the gene represented in this entry.
616321 OMIMMyasthenic syndrome, congenital, 3A, slow-channel (CMS3A)A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS3A is a slow-channel myasthenic syndrome. It is caused by kinetic abnormalities of the AChR, resulting in prolonged AChR channel opening episodes, prolonged endplate currents, and depolarization block. This is associated with calcium overload, which may contribute to subsequent degeneration of the endplate and postsynaptic membrane. The disease is caused by variants affecting the gene represented in this entry.
616322 OMIMMyasthenic syndrome, congenital, 3B, fast-channel (CMS3B)A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS3B is a fast-channel myasthenic syndrome. It is caused by kinetic abnormalities of the AChR, resulting in brief opening and activity of the channel, with a rapid decay in endplate current, failure to achieve threshold depolarization of the endplate and consequent failure to fire an action potential. The disease is caused by variants affecting the gene represented in this entry.

Interactions

54 interactions

InteractorPartnerSourcesPublicationsLink
CHRNDCHRNA1BioGRID, HPRD7695910 8910344 details
CHRNDGRB2HPRD9668219 details
CHRNDABCA3BioGRID, IntAct28514442 details
CHRNDBTN2A2BioGRID, IntAct28514442 details
CHRNDPKD2BioGRID, IntAct28514442 details
CHRNDDHRS7BioGRID, IntAct28514442 details
CHRNDERGIC3BioGRID, IntAct28514442 details
CHRNDSLC12A4BioGRID, IntAct28514442 details
CHRNDCCPG1BioGRID, IntAct28514442 details
CHRNDPOMT2BioGRID, IntAct28514442 details
CHRNDFAM8A1BioGRID, IntAct28514442 details
CHRNDEIF2AK3BioGRID, IntAct28514442 details
CHRNDGPRC5BBioGRID, IntAct28514442 details
CHRNDTYW1BioGRID, IntAct28514442 details
CHRNDTMEM39ABioGRID, IntAct28514442 details
CHRNDCNNM1BioGRID, IntAct28514442 details
CHRNDST7BioGRID, IntAct28514442 details
CHRNDDNAJC18BioGRID, IntAct28514442 details
CHRNDALG9BioGRID, IntAct28514442 details
CHRNDSEC11CBioGRID, IntAct28514442 details
CHRNDC1orf43BioGRID, IntAct28514442 details
CHRNDPRXL2ABioGRID, IntAct28514442 details
CHRNDAPOL2BioGRID, IntAct28514442 details
CHRNDATF6BBioGRID, IntAct28514442 details
CHRNDERGIC2BioGRID, IntAct28514442 details
CHRNDSLC47A1BioGRID, IntAct28514442 details
CHRNDEDABioGRID, IntAct28514442 details
CHRNDST7LBioGRID, IntAct28514442 details
CHRNDSPPL2BBioGRID, IntAct28514442 details
CHRNDSPPL3BioGRID, IntAct28514442 details
CHRNDPDZD8BioGRID, IntAct28514442 details
CHRNDSIDT2BioGRID, IntAct28514442 details
CHRNDCISD2BioGRID, IntAct28514442 details
CHRNDKIAA2013BioGRID, IntAct28514442 details
CHRNDATG9ABioGRID, IntAct28514442 details
CHRNDDPY19L4BioGRID, IntAct28514442 details
CHRNDTMTC3BioGRID, IntAct28514442 details
CHRNDTMPPEBioGRID, IntAct28514442 details
CHRNDLCLAT1BioGRID, IntAct28514442 details
CHRNDPLPPR3BioGRID, IntAct28514442 details
CHRNDWLSBioGRID, IntAct28514442 details
CHRNDABCC10BioGRID, IntAct28514442 details
CHRNDSLC27A3BioGRID, IntAct28514442 details
CHRNDSGCBBioGRID, IntAct28514442 details
CHRNDSQLEBioGRID, IntAct28514442 details
CHRNDTUSC3BioGRID, IntAct28514442 details
CHRNDBNIP1BioGRID, IntAct28514442 details
CHRNDSREBF2BioGRID, IntAct28514442 details
CHRNDOCA2BioGRID, IntAct28514442 details
CHRNDFAM189BBioGRID, IntAct28514442 details
CHRNDMFAP3BioGRID, IntAct28514442 details
CHRNDTMBIM6BioGRID, IntAct28514442 details
CHRNDTPST2BioGRID, IntAct28514442 details
CHRNDEXTL3BioGRID, IntAct28514442 details